BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32592745)

  • 1. Serum N-terminal pro-B-type natriuretic peptide as a predictor for future development of atrial fibrillation in a general population: the Hisayama Study.
    Nagata T; Hata J; Sakata S; Oishi E; Honda T; Furuta Y; Ohara T; Yoshida D; Hirakawa Y; Shibata M; Ide T; Kitazono T; Tsutsui H; Ninomiya T
    Int J Cardiol; 2020 Dec; 320():90-96. PubMed ID: 32592745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study.
    Nagata T; Ohara T; Hata J; Sakata S; Furuta Y; Yoshida D; Honda T; Hirakawa Y; Ide T; Kanba S; Kitazono T; Tsutsui H; Ninomiya T
    J Am Heart Assoc; 2019 Sep; 8(17):e011652. PubMed ID: 31446828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary N-terminal pro-B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study.
    Yamasaki K; Hata J; Ide T; Nagata T; Sakata S; Yoshida D; Honda T; Hirakawa Y; Nakano T; Kitazono T; Tsutsui H; Ninomiya T
    Environ Health Prev Med; 2021 Apr; 26(1):47. PubMed ID: 33845756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
    Xiao J; Persson AP; Engström G; Johnson LSB
    BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation.
    Giannopoulos G; Kossyvakis C; Angelidis C; Efremidis M; Panagopoulou V; Letsas K; Bouras G; Vassilikos VP; Goudevenos J; Tousoulis D; Lekakis J; Deftereos S
    Heart Rhythm; 2015 Jul; 12(7):1470-5. PubMed ID: 25847478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study.
    Kumarathurai P; Mouridsen MR; Mattsson N; Larsen BS; Nielsen OW; Gerds TA; Sajadieh A
    Europace; 2017 Mar; 19(3):364-370. PubMed ID: 27194537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.
    Li L; Selvin E; Lutsey PL; Hoogeveen RC; O'Neal WT; Soliman EZ; Chen LY; Alonso A
    Am Heart J; 2018 Oct; 204():119-127. PubMed ID: 30099337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.
    Patton KK; Ellinor PT; Heckbert SR; Christenson RH; DeFilippi C; Gottdiener JS; Kronmal RA
    Circulation; 2009 Nov; 120(18):1768-74. PubMed ID: 19841297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.
    Werhahn SM; Becker C; Mende M; Haarmann H; Nolte K; Laufs U; Zeynalova S; Löffler M; Dagres N; Husser D; Dörr M; Gross S; Felix SB; Petersmann A; Herrmann-Lingen C; Binder L; Scherer M; Hasenfuß G; Pieske B; Edelmann F; Wachter R
    ESC Heart Fail; 2022 Feb; 9(1):100-109. PubMed ID: 34850596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
    Xing LY; Diederichsen SZ; Højberg S; Krieger DW; Graff C; Frikke-Schmidt R; Olesen MS; Brandes A; Køber L; Haugan KJ; Svendsen JH
    Circulation; 2023 Jun; 147(24):1788-1797. PubMed ID: 37061802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study.
    Almuwaqqat Z; O'Neal WT; Norby FL; Lutsey PL; Selvin E; Soliman EZ; Chen LY; Alonso A
    J Am Heart Assoc; 2019 Oct; 8(19):e013294. PubMed ID: 31564186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
    Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
    BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated admission N-terminal pro-brain natriuretic peptide level predicts the development of atrial fibrillation in general surgical intensive care unit patients.
    Chokengarmwong N; Yeh DD; Chang Y; Ortiz LA; Kaafarani HMA; Fagenholz P; King DR; DeMoya M; Butler K; Lee J; Velmahos G; Januzzi JL; Lee-Lewandrowski E; Lewandrowski K
    J Trauma Acute Care Surg; 2017 Sep; 83(3):485-490. PubMed ID: 28463935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide over N-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke.
    Palà E; Pagola J; Juega J; Francisco-Pascual J; Bustamante A; Penalba A; Comas I; Rodriguez M; De Lera Alfonso M; Arenillas JF; de Torres R; Pérez-Sánchez S; Cabezas JA; Moniche F; González-Alujas T; Molina CA; Montaner J
    Eur J Neurol; 2021 Feb; 28(2):540-547. PubMed ID: 33043545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
    Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SERUM cardiac-specific biomarkers and atrial fibrillation in myotonic dystrophy type I.
    Russo V; Rago A; Atripaldi L; Leonardi S; Papa AA; Politano L; Golino P; Potpara TS; Nigro G
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2914-2919. PubMed ID: 31579995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.